Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:cyclopentanones
go back to main search page
Accession:CHEBI:36140 term browser browse the term
Definition:Any alicyclic ketone that consists of a cyclopentane skeleton substituted by at least one oxo group.


show annotations for term's descendants           Sort by:
 
16,16-dimethylprostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
ISO 16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]
CTD PMID:15578100 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases response to substance
affects localization
ISO BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2
16,16-Dimethylprostaglandin E2 affects the localization of BAX protein
CTD PMID:15578100 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] CTD PMID:15578100 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases activity ISO 16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein CTD PMID:14736730 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein] CTD PMID:11686837, PMID:11855677, PMID:11991626, PMID:18306037 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] CTD PMID:11686837, PMID:11855677, PMID:11991626, PMID:15610444, PMID:18306037 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA]
16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]
CTD PMID:9099957, PMID:15610444 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO 16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] CTD PMID:9298541 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
AH23848 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein CTD PMID:19407222 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Arrb1 arrestin, beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein CTD PMID:19407222 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Axin1 axin 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein] CTD PMID:19407222
G Bad BCL2-associated agonist of cell death multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein CTD PMID:19407222 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein CTD PMID:19407222 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein CTD PMID:19407222 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein CTD PMID:19407222 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein
AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]
CTD PMID:19407222, PMID:32115946 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein CTD PMID:19407222 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] CTD PMID:20678559, PMID:28571770 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] CTD PMID:20093341 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein CTD PMID:19407222 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of EGR1 protein CTD PMID:19407222 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of FOS protein CTD PMID:19407222 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein CTD PMID:19407222 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein CTD PMID:19407222 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of JUN protein CTD PMID:19407222 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Lep leptin multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] CTD PMID:28571770 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein CTD PMID:19407222 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein CTD PMID:19407222 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MYC protein CTD PMID:19407222 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of NFKB1 protein CTD PMID:19407222 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of NFKBIA protein CTD PMID:19407222 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein CTD PMID:19407222 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein] CTD PMID:19407222 NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein] CTD PMID:19407222 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] CTD PMID:20678559 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein CTD PMID:19407222 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of SP1 protein CTD PMID:19407222 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein CTD PMID:19407222 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Tcf7 transcription factor 7 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7 protein CTD PMID:19407222 NCBI chr10:37,616,033...37,646,027
Ensembl chr10:37,617,279...37,645,802
JBrowse link
G Tcf7l2 transcription factor 7 like 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7L2 protein CTD PMID:19407222 NCBI chr 1:276,686,911...276,730,517
Ensembl chr 1:276,659,542...276,730,514
Ensembl chr 1:276,659,542...276,730,514
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] CTD PMID:9298541 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein CTD PMID:19407222 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
cyclopentanone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions
increases reduction
ISO [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:23261716 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions
increases reduction
ISO [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:23261716 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
loxoprofen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase increases activity EXP loxoprofen results in increased activity of MPO protein CTD PMID:20586851 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming multiple interactions
decreases expression
EXP lafutidine inhibits the reaction [loxoprofen results in decreased expression of MUC2] CTD PMID:20586851 NCBI chr 1:214,663,929...214,693,197 JBrowse link
G Nos2 nitric oxide synthase 2 increases expression
multiple interactions
EXP loxoprofen results in increased expression of NOS2
lafutidine inhibits the reaction [loxoprofen results in increased expression of NOS2]
CTD PMID:20586851 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19810
    chemical entity 19810
      atom 19808
        nonmetal atom 19683
          carbon atom 19588
            organic molecular entity 19588
              aliphatic compound 13859
                alicyclic compound 1466
                  alicyclic ketone 1049
                    cyclopentanones 40
                      (+)-jasmonic acid 0
                      (4Z)-7-\{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl\}hept-4-enoic acid + 34
                      (9R,13R)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoic acid 0
                      12-hydroxyjasmonic acid + 0
                      16,16-dimethylprostaglandin E2 8
                      cyclopentane-1,3-dione 0
                      cyclopentanone 2
                      loxoprofen + 3
                      methyl tuberonate 0
                      tuberonic acid + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19810
    subatomic particle 19808
      composite particle 19808
        hadron 19808
          baryon 19808
            nucleon 19808
              atomic nucleus 19808
                atom 19808
                  main group element atom 19696
                    p-block element atom 19696
                      carbon group element atom 19599
                        carbon atom 19588
                          organic molecular entity 19588
                            organic group 18527
                              organic divalent group 18520
                                organodiyl group 18520
                                  carbonyl group 18427
                                    carbonyl compound 18427
                                      ketone 16171
                                        cyclic ketone 13874
                                          alicyclic ketone 1049
                                            cyclopentanones 40
                                              (+)-jasmonic acid 0
                                              (4Z)-7-\{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl\}hept-4-enoic acid + 34
                                              (9R,13R)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoic acid 0
                                              12-hydroxyjasmonic acid + 0
                                              16,16-dimethylprostaglandin E2 8
                                              cyclopentane-1,3-dione 0
                                              cyclopentanone 2
                                              loxoprofen + 3
                                              methyl tuberonate 0
                                              tuberonic acid + 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.